<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563782</url>
  </required_header>
  <id_info>
    <org_study_id>7317-CL-0002</org_study_id>
    <secondary_id>MA09-hRPE AMD 02 PORTRAY</secondary_id>
    <nct_id>NCT02563782</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD</brief_title>
  <acronym>PORTRAY</acronym>
  <official_title>Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Institute for Regenerative Medicine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of 3 regimens of short-term, low-dose systemic IMT as rejection&#xD;
      prophylaxis prior to and/or following transplant of MA09-hRPE cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a Phase 2, double-masked, randomized, parallel group, sham surgery/placebo&#xD;
      control, multi-center trial. Subjects will be randomized in a 3:1 ratio to either the&#xD;
      treatment or control group respectively. Subjects randomized to the treatment group will&#xD;
      receive transplantation with 200,000 MA09-hRPE (human embryonic stem cell derived retinal&#xD;
      pigmented epithelial)cells in one eye. Subjects randomized to the control group will have a&#xD;
      sham surgery without transplantation of MA09-hRPE cells. The study eye must meet all&#xD;
      eligibility criteria. If both eyes meet all eligibility criteria, then the study eye will be&#xD;
      the eye with the worst Best Corrected Visual Acuity (BCVA) score at screening. If both eyes&#xD;
      have identical BCVA scores, then the study eye will be chosen by the Investigator and the&#xD;
      subject. There will be 3 cohorts, each with a different regimen of low-dose IMT [tacrolimus&#xD;
      and mycophenolate mofetil (MMF)]. Subjects will be randomized to treatment or control within&#xD;
      cohorts, defined by severity of BCVA in the study eye at Screening. Enrollment in Cohort 1&#xD;
      and 2 will be concurrent. Enrollment into Cohort 3 will begin once Cohort 2 is fully&#xD;
      enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Changes to the study design and the cell line&#xD;
  </why_stopped>
  <start_date type="Actual">August 24, 2015</start_date>
  <completion_date type="Actual">May 5, 2017</completion_date>
  <primary_completion_date type="Actual">May 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with evidence of graft failure or rejection.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in area of geographic atrophy by Optical coherence tomography</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline to Week 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in area of geographic atrophy by Autofluorescence</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline to Week 78</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline to Week 78</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham surgery and placebo immunosuppressive therapy (IMT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sub-retinal transplantation of MA09-hRPE cells and IMT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sub-retinal transplantation of MA09-hRPE cells</intervention_name>
    <description>transplantation</description>
    <arm_group_label>Active Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus and mycophenolate mofetil</intervention_name>
    <description>Immunosuppressive Agents</description>
    <arm_group_label>Active Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tacrolimus and mycophenolate mofetil</intervention_name>
    <description>placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Surgery</intervention_name>
    <description>Sham surgery</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Geographic atrophy (GA) secondary to AMD with no evidence of prior to active choroidal&#xD;
             neovascularization (CNV) in the study eye.&#xD;
&#xD;
          -  BCVA in the study eye must be between 4 and 58 Early Treatment of Diabetic Retinopathy&#xD;
             Study (EDTRS) letters (20/800 to 20/80; 0.025-0.25)&#xD;
&#xD;
          -  Subjects must be willing to take IMT and willing to discontinue any medication that&#xD;
             has a known strong interaction with tacrolimus or mycophenolate mofetil (MMF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular atrophy due to causes other than AMD&#xD;
&#xD;
          -  Other sight-threatening ocular disease&#xD;
&#xD;
          -  Current or prior history of optic neuropathy, retinal dystrophy, retinitis pigmentosa,&#xD;
             chorioretinitis, vasoocclusive disease, retinal vascular disease or retinal&#xD;
             degenerative disease OTHER than AMD&#xD;
&#xD;
          -  History of uveitis&#xD;
&#xD;
          -  History of allergic reaction to sulfa drugs&#xD;
&#xD;
          -  Solid organ or bone marrow transplant recipient&#xD;
&#xD;
          -  History of malignancy within the previous 5 years (except for BCC (basal cell&#xD;
             carcinoma), SCC (squamous cell carcinoma) or in-situ cervical)&#xD;
&#xD;
          -  History of myocardial infarction with past 12 months&#xD;
&#xD;
          -  History of clinically significant cardiac dysrhythmia&#xD;
&#xD;
          -  History of diabetes mellitus, bowel disease, tuberculosis&#xD;
&#xD;
          -  Prior treatment for non-exudative AMD&#xD;
&#xD;
          -  Intraocular, refractive or cataract surgery in the last 12 weeks&#xD;
&#xD;
          -  Prior retinal surgery, vitrectomy, macular laser photocoagulation, external beam&#xD;
             radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or&#xD;
             corneal surgery (except cataract surgery)&#xD;
&#xD;
          -  Receipt of gene transfer of cell transplant therapy in a prior clinical trial&#xD;
&#xD;
          -  Participation in any other interventional clinical trial within the last 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Institute for Regenerative Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

